In this single-arm trial, the median overall survival (OS) observed was 4.0 months (95% CI: 2.5-7.2) among all 64 adults in the primary efficacy analysis based on the Kaplan-Meier estimate. The median ...

The FDA approval of Monjuvi was based on data from the MorphoSys-sponsored phase ... reactions, serious or severe myelosuppression (including neutropenia (50%), thrombocytopenia (18%), and anemia ...

The most common adverse reactions reported during the trial were upper respiratory tract infections, headache, fatigue, peripheral edema, cough, anemia, rash, herpes zoster, and nausea.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2025 financial results and provided a corporate update.

Apr. 18, 2025 — A team led by researchers say public ignorance and apathy towards bird flu (highly pathogenic avian influenza, or HPAI) could pose a serious obstacle to containing the virus and ...

Notably, moxifloxacin and gatifloxacin are being tested for shortening treatment in Phase III trials, while three novel compounds, TMC-207, OPC-67683 and PA-824 are in Phase II studies for both ...

The evolution of TBI involves the body's reaction to injury and begins within ... Brief periods of hyperventilation can be used to treat acute neurologic deterioration, while longer periods ...

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 ... common adverse reactions reported during the trial were upper respiratory tract infections, headache, ...

A new study conducted in Italy reveals a reduction in long-COVID burden 7 months following the acute phase. The study, published in BMC Infectious Diseases, also shows that one-third of patients ...